Alumis, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2021-01-01
- Employees
- 11
- Market Cap
- $685.4M
- Website
- http://www.alumis.com
A Study in Patients with Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Alumis Inc
- Target Recruit Count
- 840
- Registration Number
- NCT06588738
- Locations
- 🇨🇦
CCA Medical Research Corp, Ajax, Ontario, Canada
🇨🇦SKiN Health, Cobourg, Ontario, Canada
🇨🇦Kingsway Clinical Research, Etobicoke, Ontario, Canada
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients with Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Alumis Inc
- Target Recruit Count
- 840
- Registration Number
- NCT06586112
- Locations
- 🇺🇸
MetroMed Clinical Trials, Chicago, Illinois, United States
🇺🇸MetroBoston Clinical Partners, Brighton, Massachusetts, United States
🇺🇸Cleaver Dermatology, Kirksville, Missouri, United States
Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus
- Conditions
- SLE
- Interventions
- Drug: ESK-001Drug: Placebo
- First Posted Date
- 2023-07-28
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Alumis Inc
- Target Recruit Count
- 388
- Registration Number
- NCT05966480
- Locations
- 🇺🇸
Investigator Site #1189, Sparta, New Jersey, United States
🇺🇸Investigator Site #1195, Carrollton, Texas, United States
🇺🇸Investigator site #1178, Houston, Texas, United States
POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIU
- Conditions
- Noninfectious PanuveitisUveitis Posterior Non-InfectiousUveitis, Intermediate
- Interventions
- Drug: ESK-001
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Alumis Inc
- Target Recruit Count
- 36
- Registration Number
- NCT05953688
- Locations
- 🇺🇸
Investigator Site #1076, Palisades Park, New Jersey, United States
🇺🇸Investigator Site #1064, Erie, Pennsylvania, United States
🇺🇸Investigator Site #1073, Los Angeles, California, United States
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis
- Conditions
- Plaque Psoriasis
- Interventions
- Drug: ESK-001
- First Posted Date
- 2023-02-22
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Alumis Inc
- Target Recruit Count
- 165
- Registration Number
- NCT05739435
- Locations
- 🇺🇸
Investigator Site #1018, Los Angeles, California, United States
🇺🇸Investigator Site #1035, Macon, Georgia, United States
🇺🇸Investigator Site #1017, Owensboro, Kentucky, United States
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis
- Conditions
- Plaque Psoriasis
- Interventions
- Drug: ESK-001Drug: Placebo
- First Posted Date
- 2022-10-31
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Alumis Inc
- Target Recruit Count
- 228
- Registration Number
- NCT05600036
- Locations
- 🇺🇸
Investigator Site #1035, Macon, Georgia, United States
🇺🇸Investigator Site #1017, Owensboro, Kentucky, United States
🇺🇸Investigator Site #1031, New Brighton, Minnesota, United States
Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy Participants
- Conditions
- Safety and Tolerability
- Interventions
- Other: Placebo
- First Posted Date
- 2022-06-24
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- Alumis Inc
- Target Recruit Count
- 49
- Registration Number
- NCT05431634
- Locations
- 🇺🇸
Alumis Central site, Glendale, California, United States
Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- Alumis Inc
- Target Recruit Count
- 14
- Registration Number
- NCT05330858
- Locations
- 🇺🇸
Alumis Central Site, Glendale, California, United States